Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Apr 2017 Planned number of patients changed from 120 to 200.
- 29 Mar 2017 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.